NASDAQ:CLSNCelsion Stock Price, Forecast & News

Celsion's stock was trading at $0.99 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, CLSN shares have increased by 11.1% and is now trading at $1.10.
View which stocks have been most impacted by COVID-19.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Celsion in the last year. There are currently 2 hold ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Celsion.

Celsion is scheduled to release its next quarterly earnings announcement on Friday, August 14th 2020.
View our earnings forecast for Celsion.

Celsion Co. (NASDAQ:CLSN) issued its quarterly earnings data on Thursday, March, 26th. The biotechnology company reported ($0.10) EPS for the quarter, topping analysts' consensus estimates of ($0.20) by $0.10. The biotechnology company had revenue of $0.13 million for the quarter, compared to the consensus estimate of $0.13 million. Celsion had a negative return on equity of 120.14% and a negative net margin of 3,908.00%.
View Celsion's earnings history.

Celsion's stock reverse split before market open on Tuesday, May 30th 2017. The 1-14 reverse split was announced on Friday, May 26th 2017. The number of shares owned by shareholders was adjusted after the market closes on Friday, May 26th 2017. An investor that had 100 shares of Celsion stock prior to the reverse split would have 7 shares after the split.

2 equities research analysts have issued 12 month target prices for Celsion's stock. Their forecasts range from $4.00 to $4.00. On average, they expect Celsion's share price to reach $4.00 in the next twelve months. This suggests a possible upside of 263.6% from the stock's current price.
View analysts' price targets for Celsion.

News articles about CLSN stock have trended negative this week, InfoTrie Sentiment reports. The research firm rates the sentiment of media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Celsion earned a news impact score of -2.4 on InfoTrie's scale. They also gave headlines about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the immediate future.
View the latest news about Celsion.

Celsion saw a increase in short interest during the month of December. As of December 31st, there was short interest totaling 204,400 shares, an increase of 49.9% from the December 15th total of 136,400 shares. Based on an average trading volume of 194,100 shares, the days-to-cover ratio is currently 1.1 days.
View Celsion's Short Interest.

Some companies that are related to Celsion include Minerva Neurosciences (NERV), Evofem Biosciences (EVFM), CELYAD SA/ADR (CYAD), Genprex (GNPX), Adamas Pharmaceuticals (ADMS), ESSA Pharma (EPIX), Eton Pharmaceuticals (ETON), Evoke Pharma (EVOK), Mallinckrodt (MNK), OASMIA PHARMACE/ADR (OASM), Mustang Bio (MBIO), Obseva (OBSV), Tonix Pharmaceuticals (TNXP), Evolus (EOLS) and Axovant Gene Therapies (AXGT).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Celsion investors own include Chesapeake Energy (CHKAQ), Chesapeake Energy (CHKAQ), Zosano Pharma (ZSAN), Novan (NOVN), Sorrento Therapeutics (SRNE), AEterna Zentaris (AEZS), Matinas BioPharma (MTNB), Agenus (AGEN), CBL & Associates Properties (CBL) and Dynavax Technologies (DVAX).

Celsion trades on the NASDAQ under the ticker symbol "CLSN."

Celsion's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Envestnet Asset Management Inc. (0.08%), Park Avenue Securities LLC (0.08%) and Total Investment Management Inc. (0.08%). Company insiders that own Celsion stock include Alberto R Martinez Jr, Frederick J Fritz, Jeffrey Wayne Church, Michael H Tardugno and Robert W Hooper.
View institutional ownership trends for Celsion.

CLSN stock was acquired by a variety of institutional investors in the last quarter, including Park Avenue Securities LLC, Envestnet Asset Management Inc., and Total Investment Management Inc.. Company insiders that have bought Celsion stock in the last two years include Alberto R Martinez Jr, Frederick J Fritz, Jeffrey Wayne Church, Michael H Tardugno, and Robert W Hooper.
View insider buying and selling activity for Celsion.

Shares of CLSN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of CLSN stock can currently be purchased for approximately $1.10.

Celsion has a market capitalization of $36.56 million and generates $500,000.00 in revenue each year. The biotechnology company earns $-16,850,000.00 in net income (profit) each year or ($0.91) on an earnings per share basis. Celsion employs 29 workers across the globe.

The official website for Celsion is www.celsion.com.

Celsion's mailing address is 997 LENOX DRIVE SUITE 100, LAWRENCEVILLE NJ, 08648. The biotechnology company can be reached via phone at 609-896-9100 or via email at [email protected]